Oxamyl

Oxamyl

SCHEMBL2239191

CNC(=O)ON=C(SC)C(=O)N(C)C.NC(=O)O

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxamyl SCHEMBL21327715 1.00 TDP1 (0.35) TDP1
Oxamyl SCHEMBL9276500 0.95 TDP1 (0.36) TDP1
Oxamyl SCHEMBL26950 0.95 TDP1 (0.38) TDP1
Oxamyl SCHEMBL1765917 0.95 TDP1 (0.38) TDP1
Oxamyl SCHEMBL5802654 0.95 TDP1 (0.38) TDP1
Oxamyl SCHEMBL7871702 0.95 TDP1 (0.38) TDP1
Oxamyl SCHEMBL5695469 0.93 TDP1 (0.37) TDP1
Oxamyl SCHEMBL28371792 0.89 TDP1 (0.34) TDP1
Oxamyl SCHEMBL28442757 0.89 TDP1 (0.34) TDP1
Oxamyl SCHEMBL3246496 0.88 TDP1 (0.33) TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105246336-B Use of tetramic acid derivatives as nematicides 先正达参股股份有限公司 2022-08-30 CN claimed
US-10246459-B2 Use of tetramic acid derivatives as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2019-04-02 US claimed
US-20180030052-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2018-02-01 US claimed
EP-3003041-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES Syngenta Participations AG (CH) 2016-04-13 EP claimed
US-20160090384-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-03-31 US claimed
CN-105246336-A Use of tetramic acid derivatives as nematicides SYNGENTA PARTICIPATIONS AG 2016-01-13 CN claimed
WO-2014191271-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-12-04 WO claimed
WO-2011100424-A1 METHODS FOR REDUCING NEMATODE DAMAGE TO PLANTS BAYER CROSCIENCE LP (US) 2011-08-18 WO claimed
US-20110200571-A1 Methods for Reducing Nematode Damage to Plants BELL JOHN W 2011-08-18 US claimed
CN-105246336-B Use of tetramic acid derivatives as nematicides 先正达参股股份有限公司 2022-08-30 CN disclosed
CN-113811520-A Agricultural adjuvant comprising microfibrillated cellulose 艾姆瓦克香港有限公司 2021-12-17 CN disclosed
CN-113727605-A Pesticide formulations comprising MFC as rheology modifier 艾姆瓦克香港有限公司 2021-11-30 CN disclosed
EP-3003041-B1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2020-03-18 EP disclosed
US-10246459-B2 Use of tetramic acid derivatives as nematicides SYNGENTA PARTICIPATIONS AG (CH) 2019-04-02 US disclosed
EP-3003041-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES Syngenta Participations AG (CH) 2016-04-13 EP disclosed
US-20160090384-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2016-03-31 US disclosed
CN-105246336-A Use of tetramic acid derivatives as nematicides SYNGENTA PARTICIPATIONS AG 2016-01-13 CN disclosed
WO-2014191271-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-12-04 WO disclosed
WO-2011100424-A1 METHODS FOR REDUCING NEMATODE DAMAGE TO PLANTS BAYER CROSCIENCE LP (US) 2011-08-18 WO disclosed
US-20110200571-A1 Methods for Reducing Nematode Damage to Plants BELL JOHN W 2011-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030052-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES TBCA, TUBB, TUBA1C TDP1 1792/4885
US-20160090384-A1 USE OF TETRAMIC ACID DERIVATIVES AS NEMATICIDES TBCA, TUBB, TUBA1C TDP1 1792/4885
US-10246459-B2 Use of tetramic acid derivatives as nematicides TBCA, TUBB, TUBA1C TDP1 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.